Digital Content 
NEWS #PharmaBuzz
21 May 2026
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2026/05/21/3299597/0/en/the-european-medicines-agency-accepts-teva-s-marketing-authorization-application-for-olanzapine-long-acting-injectable-tev-749-for-the-treatment-of-schizophrenia-in-adults.html
05 May 2026
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2026/05/05/3287601/32445/en/minerva-neurosciences-provides-first-quarter-2026-financial-results-and-business-updates.html
14 Apr 2026
// BUSINESSWIRE
https://www.businesswire.com/news/home/20260414639785/en/Findings-From-Long-Term-Analysis-of-the-Effects-of-LYBALVI-olanzapine-and-samidorphan-on-Negative-Symptoms-of-Schizophrenia-Published-in-The-Journal-of-Clinical-Psychiatry
25 Mar 2026
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2026/03/25/3262573/32445/en/Minerva-Neurosciences-Presents-Data-from-its-Open-label-Safety-Trial-Evaluating-Roluperidone-Co-administered-with-Olanzapine-at-SIRS-2026.html
05 Mar 2026
// FDA
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=220323
23 Jan 2026
// FDA
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=219048
Share